Introduction {#s1}
============

During the non-pacemaker action potential (AP) in the heart, depolarization of the cell membrane opens voltage gated sodium channels (Na~v~) for a short period of time ([@B157]; [@B133]) giving rise to the early sodium current peak (I~Na,early~). This I~Na,early~ causes the upstroke of the non-pacemaker AP. Through the course of the AP Na~v~ channels may recover from inactivation and reopen, generating a sustained current component, called late sodium current (I~Na,late~). I~Na,late~ flows throughout the plateau phase of the AP therefore it significantly contributes to AP morphology, even though its magnitude is only a fraction of I~Na,early~ ([**Figure 1A**](#f1){ref-type="fig"}).

![The early and the late component of the sodium current under physiological **(A)** and pathological **(B)** conditions. Upper panels: membrane potential; lower panels: sodium current. I~Na,early~, early (peak) component of the sodium current; I~Na,late~, late (sustained) component of the sodium current.](fphar-11-00413-g001){#f1}

If I~Na,late~ is increased, it might play a pathophysiological role in acquired cardiac diseases ([**Figure 1B**](#f1){ref-type="fig"}) such as myocardial ischemia ([@B116]) and heart failure ([@B53]; [@B148]). In the cardiomyocytes, an upregulated I~Na,late~ hinders repolarization and causes a larger sodium entry, therefore increasing intracellular sodium concentration (\[Na^+^\]~i~). An increased \[Na^+^\]~i~, in turn, leads to a larger intracellular calcium content. These factors together can possibly cause contractile dysfunction ([@B174]), disturbed myocardial energetics ([@B106]) and cardiac arrhythmias ([@B11]).

Electrophysiological Identification of I~Na,late~ {#s2}
=================================================

Mammalian cardiac cells express a wide variety of Na~v~ isoforms, differing in unit conductance, voltage sensitivity, kinetics, and drug sensitivity. In the majority of cardiac tissues, the dominant isoform of the pore-forming subunit is Na~v~1.5, which is relatively insensitive to the sodium channel toxin tetrodotoxin (TTX) ([@B67]; [@B43]). Many of the TTX-sensitive ("non-cardiac") Na~v~ channels (Na~v~1.1, Na~v~1.2, Na~v~1.3, Na~v~1.4, and Na~v~1.6) are also shown to be present in cardiac tissue ([@B117]; [@B75]; [@B188]; [@B28]; [@B208]). In nodal tissue Na~v~1.1 and Na~v~1.6 are expressed in the largest quantities. Besides the pore-forming subunit, four auxiliary subunits (ß~1~, ß~2~, ß~3~, and ß~4~) and certain scaffolding proteins also participate in building up the whole complex, which also attaches to the cytoskeleton. These molecules can interact with each other and may modify the kinetics and voltage dependence of the actual channel ([@B122]).

Mechanisms that are discussed in the followings may contribute to the profile of I~Na,late~ during the AP. Understanding these mechanisms better might be helpful in developing new antiarrhythmic therapeutic strategies targeting I~Na,late~.

I~Na,late~ Is Underlain by Different Channel Gating Modes {#s2_1}
---------------------------------------------------------

At the resting membrane potential, the vast majority of Na~v~1.5 channels are in their closed state. Upon depolarization, Na~v~1.5 channels open up within 1--2 ms after which they inactivate rapidly ([@B157]; [@B133]). This produces I~Na,early~ and the upstroke of the non-pacemaker cardiac AP. During a sustained depolarization, Na~v~1.5 channels can reopen with a small probability. In ventricular myocytes, three modes of Nav1.5 channel activity have been characterized in single-channel experiments: transient mode (TM), burst mode (BM), and late scattered mode (LSM) ([@B128]).

I~Na,early~ is mainly the result of TM activity, while BM and LSM are responsible for the sustained sodium current, I~Na,late~ ([**Figure 1A**](#f1){ref-type="fig"}). The magnitude of the sustained current component is only about 0.5--1 % of I~Na,early~ measured 50 ms after the onset of the depolarizing pulse ([@B128]). During a sustained depolarization BM openings rapidly decline in the first tens of milliseconds therefore leaving LSM as the gating mode being mainly responsible for I~Na,late~ toward the end of the plateau phase.

Mutations of the channel protein and certain diseases can change the contribution of different Na~v~1.5 channel activity patterns to the macroscopic current, therefore increasing I~Na,late~ ([@B27]; [@B188]; [@B203]; [@B125]; [@B123]; [@B171]; [@B127]; [@B205]; [@B71]; [@B182]) ([**Figure 1B**](#f1){ref-type="fig"}). Apparently, each gating mode has a distinct drug sensitivity or drug affinity as well ([@B17]; [@B150]; [@B18]). Based on this, selective pharmacological targeting of certain gating modes might have potential antiarrhythmic and/or cardioprotective effects ([@B18]; [@B82]; [@B134]).

Window Sodium Current {#s2_2}
---------------------

The voltage dependence of the steady state activation and inactivation of most Na~v~ channels overlaps with each other ([@B213]). This overlap provides a voltage range ("window") where inactivated Na~v~ channels are able to recover from inactivation and then might reopen. When the actual membrane potential falls within this "window" of overlap, a sustained current is evoked. Under physiological circumstances this "window current" mechanism likely plays a limited role in I~Na,late~, because the Na~v~1.5 voltage "window" is around −70 mV, falling quite far from the AP plateau. Additionally, in the window voltage range, the current density is less than 5 % of the maximum current density in healthy myocytes ([@B124]; [@B196]; [@B107]). Hence, the "window current" mechanism is unlikely to be a major determinant of I~Na,late~ in healthy myocytes. Mutations of channel proteins or altered regulation in certain diseases may shift either the steady-state activation or inactivation curves of Na~v~ channels to significantly change this voltage window, therefore increasing I~Na,late~ under these pathological conditions ([@B195]; [@B154]).

Non-Equilibrium Channel Gating {#s2_3}
------------------------------

During the AP of cardiac myocytes, the membrane potential changes continuously. Na~v~ channels are incorporated into this dynamic system. It has been proposed by [@B49] that the voltage "history" of the cell membrane can modulate the transition between Na~v~ channel states, termed "non-equilibrium gating". As a result, recovery from inactivation is also modulated by the dynamics of voltage change. The theory is supported by experimental data showing that the application of repolarizing voltage ramps or AP shape voltage commands evoke a larger I~Na,late~ compared to conventional square pulses or model simulations where "non-equilibrium gating" is not incorporated into the numerical model ([@B49]; [@B115]; [@B80]).

Non-Cardiac Sodium Channel Isoforms in the Heart {#s2_4}
------------------------------------------------

Epilepsy ([@B6]; [@B5]) and certain skeletal muscle diseases ([@B97]; [@B141]) has been associated with pathological ECG recordings. Therefore it seemed possible that non-cardiac sodium channel mutations might cause electrical alterations in the heart. Later, Na~v~1.1, Na~v~1.2, Na~v~1.3, Na~v~1.4, Na~v~1.6, and Na~v~1.8 isoforms have been identified in cardiac tissue ([@B117]; [@B75]; [@B188]; [@B28]; [@B208]). Based on the findings of *Biet et al*., as much as 44 % of I~Na,late~ is due to non-cardiac sodium channels ([@B28]) in canine ventricular cardiomyocytes. Furthermore, *Yang et al*. have shown that in mice and rabbit the TTX-resistant Na~v~1.8 provides a substantial amount of I~Na,late~ ([@B208]). Based on these experimental data, isoform specific sodium channel modulators might provide a valid approach in pharmacological antiarrhythmic therapy (See *Non-Cardiac Sodium Channel Inhibitors as Potential Antiarrhythmic Agent* for further details).

Role of I~Na,late~ in Cardiac Physiology {#s3}
========================================

Role of I~Na,late~ in Cardiac Electrical Activity {#s3_1}
-------------------------------------------------

Contribution of I~Na,late~ to cardiac APs was questioned because of its small density. However, the plateau phase of the cardiac AP is shaped by a delicate balance between minuscule inward and outward current fluxes. Therefore even a small change in these currents may significantly alter the duration of the AP ([@B79]). Inhibition of I~Na,late~ substantially shortens the cardiac AP in the conductive system ([@B54]) and in ventricular cells ([@B94]) as well, indicating that I~Na,late~ significantly contributes to determining the duration of the non-pacemaker AP in cardiac myocytes. Recent AP voltage clamp experiments show that the density of I~Na,late~ is of similar magnitude as the major potassium currents in guinea pig ([@B80]) and rabbit ([@B78]) ventricular myocytes. There is a characteristic interspecies difference in the shape of I~Na,late~ as shown in the case of guinea pig, canine, and human ventricular myocytes ([@B81]).

The sustained sodium current is also an important factor in determining electrophysiological properties of sinoatrial node cells ([@B118]; [@B99]). Tetrodotoxin, applied in lower than 1 µM concentrations, reduces the rate of spontaneous depolarization in sinoatrial node cells ([@B84]), clearly indicating that non-cardiac Na~v~ isoforms also contribute to cardiac automaticity.

Cardiac Purkinje cells have the largest rate-dependence of their AP duration (APD) among cardiomyocytes with fast response APs. Purkinje cell APs are longer at lower stimulation rates, while shorter at higher rates than APs of ventricular cells. It has been shown that I~Na,late~ contributes to this feature by possessing much slower decay and recovery kinetics in Purkinje cells than in ventricular cells. As a result Purkinje cell I~Na,late~ is significantly larger at low heart rates, while smaller at high heart rates compared to ventricular cells. This unique feature predisposes Purkinje cells to serve as triggers in generating arrhythmias ([@B102]).

I~Na,late~ plays a role in forming the atrial AP as well ([@B32]; [@B113]). I~Na,late~ is expected to be larger in atria than in ventricles because I~Na,~ ~early~ density is greater in atrial cells under similar conditions ([@B101]; [@B34]), suggesting a higher sodium channel expression in atrial cells. On the other hand, an overall more positive membrane potential, and a more negative steady-state inactivation voltage of the sodium current ([@B101]; [@B34]) in the atrial cells reduce the availability of the sodium channels ([@B31]). In one set of experiments by Luo et al. maximum I~Na,late~ density has been reported to be greater in rabbit left atrial myocytes than in ventricular cells ([@B113]) and in a different investigation the two cell types seemed to be similar in this matter ([@B142]). APs are shorter in the atria compared to the ventricles reducing the amount of Na^+^ influx through I~Na,late~ in the former ([@B32]).

I~Na,late~ Plays a Significant Role in the Sodium Homeostasis of Cardiomyocytes {#s3_2}
-------------------------------------------------------------------------------

\[Na^+^\]~i~ is set by a dynamic equilibrium of the influx of Na^+^ into the cell and efflux of Na^+^ to the interstitial space. The \[Na^+^\]~i~ of non-paced ventricular myocytes is around 4--8 mM in guinea-pig, rabbit, and canine; and about twice as high in rat and mouse (9--14 mM) ([@B59]). In non-paced human myocytes \[Na^+^\]~i~ is thought to be in the 4--10 mM range.

Na^+^ can enter into the cell through Na^+^ channels, Na^+^/Ca^2+^ exchanger (NCX) and Na^+^/H^+^ exchanger (NHE). Na^+^ leaves the cell mainly via the Na^+^/K^+^ pump (NKP), but the reverse mode NCX is also responsible for a moderate Na^+^ efflux during the first few milliseconds of the cardiac AP. Furthermore, Na^+^/HCO~3~^−^ cotransport, Na^+^/Mg^2+^ exchange, and Na^+^/K^+^/2Cl^−^ cotransport can play a role in the sodium homeostasis of cardiomyocytes to a small extent ([@B59]). It also has to be mentioned that Na^+^ concentrations between the cytosol and intracellular organelles are continuously balanced.

Upon pacing, \[Na^+^\]~i~ increases with increasing stimulation frequency, caused by the larger Na^+^ entry through Na^+^ channels and NCX. In paced, single cardiac cells approximately 25 % of the Na^+^ entry is mediated by Na~v~ channels ([@B59]). The Na^+^ entry through Na~v~ channels is about equally distributed between I~Na,early~ and I~Na,late~ ([@B120]; [@B213]; [@B59]; [@B165]), however this contribution can change at different heart rates (see *Heart Rate and AP Duration Influences I~Na,late~* for details). The higher Na^+^ influx into paced cells is matched by an increased efflux through an elevated NKP activity. This is mainly caused by the increased \[Na^+^\]~i~ itself, but nitric oxide-, and phospholemman-dependent mechanisms can also add to this effect ([@B59]).

Na^+^ and Ca^2+^ Homeostasis Is Linked in Cardiomyocytes {#s3_3}
--------------------------------------------------------

### The Direct Connection Between Na^+^ and Ca^2+^ Homeostasis: Na^+^/Ca^2+^ Exchanger {#s3_3_1}

The NCX is a secondarily active transporter that carries 1 Ca^2+^ and 3 Na^+^ at the same time ([@B85]; [@B65]; [@B167]; [@B59]; [@B68]). The NCX function is determined by the relation of the actual membrane voltage and the sum of the actual electrochemical gradients of Ca^2+^ and Na^+^. The main role of NCX is to remove Ca^2+^ from the cells by utilizing the potential energy present in the form of Na^+^ gradient ("forward mode"). Besides this mode, in the first few milliseconds of the AP, NCX mediates Na^+^ extrusion from the cell and Ca^2+^ entry into the cytosol ("reverse mode").

### I~Na,late~ Facilitates Ca^2+^ Influx via L-Type Calcium Channels {#s3_3_2}

Being an inward current, I~Na,late~ depolarizes the membrane, causing an increased membrane potential throughout the plateau phase and a longer AP. The more time the membrane spends in a depolarized state (above +40 mV) the higher the possibility that L-type calcium channels can open or re-open. It is well documented with AP voltage clamp technique that the L-type calcium current is flowing throughout the AP plateau ([@B104]; [@B105]; [@B14]; [@B66]; [@B16]). Therefore a longer AP inevitably results in a larger Ca^2+^ entry to the myocyte.

Heart Rate and AP Duration Influences I~Na,late~ {#s3_4}
------------------------------------------------

Heart rate determines the magnitude of I~Na,late~. Like many electrophysiological characteristics of cardiac cells ([@B15]), I~Na,late~ is reverse-rate dependent, so the faster the stimulation rate the smaller the current density will be ([@B137]; [@B204]). However, with increasing heart rate the density of I~Na,early~ and maximum rate of depolarization during the AP upstroke (V~max~; an AP parameter determined by I~Na,early~) does not decrease that much ([@B137]). This is because recovery of I~Na,late~ is much slower than I~Na,early~ ([@B41]). At higher heart rates this feature of the two sodium current components also results in a decreasing contribution of I~Na,late~ to the overall Na^+^ influx. Under these conditions, the more frequent AP upstrokes cause a greater Na^+^ entry through I~Na,early~, and there is a reduction of I~Na,late~ density because of the very slow I~Na,late~ recovery kinetics. Moreover, rate-dependent changes of the AP length also influence Na^+^ entry. At high heart rates APs are shorter, therefore I~Na,late~ is active for a shorter time, accounting for a further reduction of Na^+^ influx through the already smaller I~Na,late~. At the same time, extrusion of Na^+^ by the NKP is reduced at high pacing rates ([@B59]) leading to a rate-dependent \[Na^+^\]~i~ loading in isolated cells. It must also be noted that this phenomenon is largely offset or may not occur at all during β-adrenergic stimulation because it augments NKP activity through phospholemman ([@B48]).).

As it is described in the previous section, APD influences I~Na,late~: the shorter the AP the smaller the Na^+^ flux through I~Na,late~ is. Therefore under any conditions that result in a shorter AP the contribution of I~Na,late~ to the overall Na^+^ influx will be smaller. This fact, together with significant differences in heart rate underlies differences in I~Na,late~ between species having short APs (e.g.: rats or mice) and long APs (guinea pig, rabbit, pig, human, etc.). In rats and mice both I~Na,late~ and Na^+^ influx driven by I~Na,late~ should be much smaller than in species having long APs.

Modulation of I~Na,late~ {#s3_5}
------------------------

### Cytosolic Ca^2+^ Modulates I~Na,late~ in a Complex Way {#s3_5_1}

Ca^2+^ is the key player in the excitation-contraction coupling of cardiac cells and it also regulates many other cellular functions including sarcolemmal transport mechanisms. Na~v~ channels are regulated by the individual and cooperative actions of Ca^2+^, calmodulin (CaM), and Ca^2+^-CaM dependent protein kinase II (CaMKII) as well ([@B22]; [@B119]; [@B158]). Signaling through the Ca^2+^---CaM---CaMKII pathway is thought to facilitate the sodium current, especially I~Na,late~ ([@B126]; [@B127]; [@B22]).

### Na~v~ Channels, Ca^2+^ and CaM {#s3_5_2}

Motifs with Ca^2+^ binding (EF hand) as well as CaM binding (IQ motifs) capabilities are present in the Na~v~1.5 channel structure. Some groups have shown that Ca^2+^ alone can regulate sodium channels ([@B201]), while other results support that Ca^2+^ is not capable of regulating Na~v~ channels directly; the regulation is mediated via Ca^2+^-CaM complex ([@B178]; [@B93]). Besides the exact regulatory mechanism, the general agreement is that when Ca^2+^ is elevated the SSI curve shifts toward more positive voltages ([@B156]), although this is a largely negligible effect at physiologically relevant Ca^2+^ concentrations in wild type channels. However, under conditions when Ca^2+^ or CaM sensing regions are mutated or when the Ca^2+^ sensitivity of Na~v~ channels are severely altered, diverse functional disturbances may arise leading to an increased I~Na,late~.

### Ca^2+^-CaM Dependent Protein Kinase II (CaMKII) {#s3_5_3}

Besides the direct regulation of Na~v~ channels, the Ca^2+^-CaM complex activates CaMKIIδ~C~ that also modulates these channels ([@B214]; [@B8]; [@B22]). The active CaMKII is a Ser/Thr kinase that can phosphorylate Na~v~1.5 channels on at least three amino acid residues ([@B70]). While there is an ongoing debate about the exact role of these phosphorylation sites in channel gating, all the studies agree on that activation of CaMKII increases I~Na,late~.

### Complex Modulation by β-Adrenergic Stimulation {#s3_5_4}

In a meticulous set of AP voltage clamp experiments, Hegyi et al. ([@B78]) showed how different downstream elements of the β-adrenergic pathway regulate I~Na,late~ in rabbit ventricular myocytes. Protein kinase A, CaMKII, Epac, nitrosylation, as well as reactive oxygen species (ROS) contributed to the upregulation of I~Na,late~ during different phases of the ventricular AP.

### Cellular Metabolites {#s3_5_5}

ROS and H~2~O~2~ increase I~Na,late~ ([@B169]; [@B170]; [@B172]). Some results suggest that CaMKII can be involved in I~Na,late~ facilitation observed in the presence of oxygen free radicals ([@B191]), because ROS can also activate CaMKII ([@B63]). See ([@B192]) for a detailed review.

Acidosis also modulates Na~v~ channels ([@B136]; [@B87]; [@B88]; [@B89]). Acidosis caused a rightward shift in steady-state activation, but not in steady-state inactivation in isolated canine ventricular myocytes therefore reducing I~Na,late~ ([@B136]).

Many studies have found that hypoxia increases I~Na,late~ ([@B90]; [@B40]; [@B74]; [@B197]; [@B164]; [@B179]). Following a 15 minute hypoxic period, *Wang et al*. reported an increased BM channel activity, a plausible explanation of the increased I~Na,late~.

Intermediary lipid metabolites shown to increase I~Na,late~. Na~v~ channels treated with lysophosphatidylcholine exhibited a sustained BM channel activity ([@B36]; [@B184]), while palmitoylcarnitine induced a slowly inactivating sodium current ([@B202]). According to more recent data, poly-unsaturated fatty acids (docosahexaenoic acid and eicosapentaenoic acid) reduce both I~Na,early~ and I~Na,late~ ([@B144]). According to the authors, the reduction is caused by a decreased overlap between the steady-state activation and inactivation voltage range.

Nitric oxide (NO) has been shown to enhance I~Na,late~ ([@B2]). The neural NO synthase (nNOS) belongs to the huge macromolecular complex of Na~v~1.5, with caveolin-3 and α1-syntrophin among some additional proteins ([@B47]).

### Other Mechanisms {#s3_5_6}

#### Transcriptional Regulation {#s3_5_6_1}

The possible promoter regions and their role in the regulation of human SCN5A gene transcription has already been reported. ([@B207]; [@B189]) Recent studies have shown that the zinc-finger transcription factor, GATA4 ([@B180]), and the myocyte enhancing factor-2C (MEF2C) enhances SCN5A transcription ([@B216]). However, most likely many other transcription factors are involved in the transcriptional regulation of the SCN5A gene.

#### Glycosylation {#s3_5_6_2}

Some amino acid motifs found in the Na~v~1.5 protein are subject to N-glycosylation. Carbohydrates account for an about 5 % of the total mass of Na~v~ channels in the rat heart ([@B51]). The lack of channel glycosylation caused shifts toward positive voltages in both steady state activation and inactivation curves when naturally sialic-acid deficient channels were used ([@B215]), or when these carbohydrate residues were removed by enzymatic treatment ([@B183]) Glycosylation also seem to be involved in channel trafficking ([@B130]; [@B55])

#### Protein Kinase C {#s3_5_6_3}

Upon protein kinase C activation, Na^+^ channels are internalized from the plasma membrane ([@B73]). For the process, both channel phosphorylation on S1503 and ROS are required ([@B108]).

#### Phosphorylation on Tyrosine Residues {#s3_5_6_4}

The "Fyn" tyrosine kinase phosphorylates Na~v~1.5 channels on the Y1495 Tyr residue, located in the III--IV linker domain. This tyrosine residue helps with anchoring Ca^2+^/CaM to the inactivation gate of the channel ([@B155]). When Fyn phosphorylates the channel on Y1495, it increases the window voltage range by shifting the steady-state inactivation toward more positive potentials ([@B3]), therefore resulting in an enhanced I~Na,late~.

#### Arginine Methylation {#s3_5_6_5}

There are three known arginine residues in Na~v~1.5 (R513, R526, and R680), that are subject to methylation ([@B20]). These residues are found in the domain I and domain II linker region. There are two known mutations of these arginines (namely R526H and R680H) that cause Brugada ([@B92]) and LQT3 syndromes ([@B198]), respectively.

#### Mechanosensitivity {#s3_5_6_6}

Mechanical stimuli also affect channel gating in Na~v~1.5 channels. *Beyder et al*. investigated this phenomenon both in an expression system ([@B25]) and in isolated mouse ventricular cells ([@B26]). The pressure ramp applied by the authors caused a 235 % increase in LSM Na~v~1.5 channel openings suggesting that I~Na,late~ is enhanced by mechanical stress. Similar mechanical effects can modify certain signal transduction mechanisms like nNOS and CaMKII ([@B86]), which can, in turn, increase I~Na,late~.

The Role of Sodium Homeostasis and Elevated I~Na,late~ in Cardiac Arrhythmias {#s4}
=============================================================================

The pathophysiology of cardiac arrhythmias is based on the classical concept of "arrhythmic triad"; combination of a proarrhythmic *substrate*, a *trigger*, and the *modulating effect of the autonomic nervous system* ([@B129]). The exact combination depends on etiology, cardiac-, and extracardiac comorbidities. Abnormal \[Na^+^\]~i~ homeostasis can play a role in creating an arrhythmia-prone substrate as well as in generating a trigger for the rhythm disorder. The discussed mechanisms are summarized on [**Figure 2**](#f2){ref-type="fig"}.

![How can an impaired sodium homeostasis of cardiac myocytes lead to arrhythmias? AP, action potential; NHE, Na^+^/H^+^ exchanger; \[Na^+^\]~i~, intracellular sodium concentration; NCX, Na^+^/Ca^2+^ exchanger; \[Ca^2+^\]~i~, intracellular calcium concentration; SR, sarcoplasmic reticulum; CaMKII, calcium/calmodulin dependent protein kinase II.](fphar-11-00413-g002){#f2}

\[Na^+^\]~i~ Increases in Many Cardiac Pathologies {#s4_1}
--------------------------------------------------

Compared to non-failing myocytes, \[Na^+^\]~i~ is about 2--6 mM larger in myocytes from failing hearts ([@B143]; [@B60]; [@B159]; [@B110]). In a pressure- and volume-overload rabbit HF model, Despa et al. have found an increased TTX-sensitive Na^+^ influx ([@B60]). Interestingly, this larger influx was present not only in electrically stimulated myocytes, but in non-paced cells as well. In paced cells the most plausible candidate of this increased TTX-sensitive Na^+^ influx is I~Na,late~. However, the underlying mechanism of this influx is not yet understood completely in resting myocytes.

I~Na,late~ Can Contribute to the Elevated \[Na^+^\]~i~ {#s4_2}
------------------------------------------------------

Many cardiac diseases are associated with an increased I~Na,late~. The list contains cardiac myocytes originating from end-stage HF ([@B124]; [@B125]) and post-myocardial infarction ([@B83]) preparations as well as animal HF models ([@B188]; [@B125]). The larger I~Na,late~ can be caused by several pathophysiologic factors including oxidative stress (ROS ([@B170]; [@B172]) and NO ([@B2]) mainly by S-nitrosylation of the Na~v~1.5 channels ([@B47])), hypoxia ([@B40]; [@B179]), mechanical stress ([@B26]), and certain ischemic metabolites, for example oxidized lipids ([@B36]). Looking at gating modes in single Na~v~1.5 channels, enhanced I~Na,late~ is likely underlain by an increased number of BM and LSM openings ([@B185]; [@B128]) in HF.

The Ca^2+^---CaM---CaMKII signal transduction pathway is upregulated in HF ([@B24]), and this pathway has been shown to increase I~Na,late~ ([@B178]; [@B190]; [@B12]; [@B114]). Oxidation activates CaMKII ([@B191]) and keeps it constitutively active. The enhanced CaMKII-mediated Na~v~1.5 phosphorylation, therefore, certainly takes part in increasing I~Na,late~ under oxidative stress. Recent studies have found that Na~v~1.8 expression is significantly up-regulated, while Na~v~1.5 is reduced in human left ventricular hypertrophy ([@B4]) and HF ([@B61]).

The Vicious Circle of CaMKII---I~Na,late~---\[Na^+^\]~i~---\[Ca^2+^\]~i~---CaMKII {#s4_3}
---------------------------------------------------------------------------------

When \[Na^+^\]~i~ is elevated, it makes the NCX forward mode energetically less favorable, therefore a smaller amount of Ca^2+^ will leave the cell through NCX. This causes an increased \[Ca^2+^\]~i~ load, and therefore further activates CaMKII, leading to enhanced phosphorylation of CaMKII targets such as Na~v~1.5. This, in turn, increases I~Na,late~, which further elevates \[Na^+^\]~i~ finally creating an arrhythmogenic vicious circle ([@B70]). By using genetic (LQT3 mutation) as well as pharmacological (anemone toxin-II, ATX-II) approaches to increase I~Na,late~, and therefore achieve \[Na^+^\]~i~ loading, Yao et al. described this feedback ([@B210]). These conditions lead to the vicious circle described above, and as a result, arrhythmias can be generated because of an increase in the CaMKII-dependent phosphorylation of phospholamban and RyRs.

\[Na^+^\]~i~---Mitochondrial \[Ca^2+^\]---Oxidative Stress---CaMKII---I~Na,late~---\[Na^+^\]~i~ Feedback {#s4_4}
--------------------------------------------------------------------------------------------------------

The mitochondrial NCX dynamically equilibrate concentrations of Ca^2+^ and Na^+^ of the mitochondrion and the cytosol. Ca^2+^ in the mitochondrion plays a role in determining the production of ATP and ROS by regulating the expression of enzymes involved in oxidative phosphorylation ([@B209]). If \[Na^+^\]~i~ is elevated, it will impair Ca^2+^ accumulation in the mitochondrion at high pacing rates, leading to a decrease in NADH/NAD^+^ redox potential. This increases H~2~O~2~ generation in the cells ([@B106]), causing oxidative stress and thereby directly and indirectly (through CaMKII ([@B63])) activating I~Na,late~. Finally, the process leads to a further increase in \[Na^+^\]~i~ ([@B191]). This shows that, similar to an elevated \[Na^+^\]~i~, CaMKII activation can be caused by and can also lead to an increased ROS production.

Arrhythmogenic Consequences of an Increased I~Na,late~ and \[Na^+^\]~i~ {#s4_5}
-----------------------------------------------------------------------

Many inherited and acquired diseases can lead to a longer ventricular repolarization, presented as long QT (LQT) syndromes ([@B62]; [@B109]). The inherited LQT3 syndrome is caused by an increased I~Na,late~ because of a mutant, much slower inactivating Na~v~1.5 channel. Acquired LQTs include for example heart failure ([@B124]; [@B125]; [@B53]), myocardial ischemia and post-infarction state ([@B83]; [@B153]), and type 2 diabetes mellitus ([@B140]).

Under physiological conditions there is a fine balance between the inward and outward currents during the AP plateau. During the plateau phase the impedance of the membrane is large, therefore even a small change in the delicate balance can lead to a marked change in AP duration. In this setting, the depolarizing drive caused by an increased I~Na,late~ causes a longer AP ([@B176]; [@B80]), as well as under a longer AP, I~Na,late~ will generate a larger Na^+^ influx. Even in normal hearts, both APD and I~Na,late~ is greater in Purkinje fibers and in "M" cells than in the rest of the myocardium contributing to the physiological heterogeneity of repolarization. LQT syndromes increase both the spatial heterogeneity of repolarization ([@B125]) and the temporal variability of repolarization ([@B62]) and therefore can present an *arrhythmogenic substrate*. This can be further exaggerated by bradycardia, where the APs are already long, and having larger heterogeneity ([@B177]). Cardiac diseases can also provide the *proarrhythmic substrate* in the form of temporal repolarization heterogeneity, "repolarization alternans" ([@B29]; [@B91]) which phenomenon is more pronounced in tachycardia.

The *trigger* is also highly rate-dependent. At low heart rates, where the cardiac APs are already long even under physiological conditions, an augmented I~Na,late~ can further prolong repolarization therefore increasing the probability of early afterdepolarizations (EADs), and the risk for (fatal) ventricular arrhythmias ([@B194]; [@B195]; [@B121]; [@B77]; [@B37]; [@B206]; [@B111]). Severe bradycardia together with an enhanced I~Na,late~ and a long APD may also promote delayed afterdepolarization (DAD)-mediated triggered activities ([@B171]; [@B53]; [@B80]). These triggered activities seem to heavily depend on an increased \[Ca^2+^\]~i~.

As described previously, an increased \[Na^+^\]~i~ offsets NCX, decreasing Ca^2+^ removal from the cytosol ([@B23]; [@B138]; [@B59]). This elevates diastolic \[Ca^2+^\]~i~ and therefore increasing SR Ca^2+^ content; leading to spontaneous Ca^2+^ release events from the Ca^2+^-overloaded SR ([@B72]). This can generate DADs and therefore possibly triggering arrhythmias. At high heart rates this can further be aggravated by the two feedback loops involving CaMKII, as described in the previous sections, resulting in an enhanced CaMKII mediated phosphorylation of RyR2 therefore increasing the probability of spontaneous SR Ca^2+^ release events. It must be noted again that *in vivo*, there is no high heart rate without β-adrenergic stimulation. Adrenergic stimulation on one hand further activates CaMKII ([@B78]) but on the other hand, it also reduces or even diminishes \[Na^+^\]~i~ loading of the cells by enhancing NKP activity ([@B48]). This makes the role of I~Na,late~ in DAD-mediated arrhythmias occurring at high heart rates questionable.

In the diseased heart, however, rate-dependent properties of I~Na,late~ and \[Na+\]i are quite poorly investigated. At high pacing rates, I~Na,late~ decreases in LQT3 ΔKPQ mutant cells ([@B137]) and an increased \[Na^+^\]~i~ load was reported in hypertrophied feline cells ([@B132]) as well as in human cardiomyocytes from failing hearts ([@B143]).

Pharmacologically enhanced I~Na,late~ increases repolarization heterogeneity in intact, isolated rabbit and guinea pig hearts ([@B152]; [@B131]), as well as in canine left ventricular wedge preparations giving rise to TdP ([@B162]; [@B163]). ATX-II also induces AF in a wide range of experimental conditions ([@B112]; [@B103]). Many gain-of-function SCN5A mutations (including LQT3) have been associated with atrial fibrillation (AF) ([@B21]). Also, in cases of chronic (permanent) AF, larger I~Na,late~ was found ([@B173]; [@B147]). These data suggest that enhancement of I~Na,late~ might play a role in generating or maintaining AF most likely because of \[Na^+^\]~i~ overload dependent Ca^2+^ overload ([@B139]).

I~Na,late~ As an Antiarrhythmic Therapeutic Target {#s5}
==================================================

Sodium Channel Inhibitors {#s5_1}
-------------------------

Natural products of peptide and non-peptide structure can inhibit sodium channels, although these compounds have negligible therapeutical relevance. Clinically relevant small-molecule sodium channel inhibitors include local anesthetics, anticonvulsants, and antiarrhythmic agents such as lidocaine, carbamazepine, phenytoin, lamotrigine, and mexiletine. These small-molecule inhibitors all bind to the so-called "local anesthetic site" of sodium channels where amino acid residues are highly conserved among different Na~v~ subtypes ([@B57]). Because of this, the "classic" Na~v~ blockers are not subtype specific, they inhibit all subtypes to a certain extent. Also, these compounds somewhat inhibit both I~Na,early~ and I~Na,late~, usually having a higher inhibitory effect on I~Na,late~. Therefore most Na~v~ blockers reduce excitability and impulse propagation (parameters associated with I~Na,early~) together with the plateau sodium current (I~Na,late~).

Selective I~Na,late~ Inhibitors {#s5_2}
-------------------------------

A few sodium channel blockers differ from the "classic" inhibitors, because they inhibit I~Na,late~ more potently than I~Na,early~. The molecular mechanism of the preferential I~Na,late~ inhibition is still not completely understood. Even though ranolazine was used for most of the experimental and clinical studies, other selective I~Na,late~ inhibitors also exist such as lidocaine, GS-458967, GS-462808, F15845, and GS-6615 (eleclazine). The half-maximal inhibitory concentration (IC~50~) values of these inhibitors for the late and the early sodium current component are summarized in [**Table 1**](#T1){ref-type="table"}. For a more thorough data summary on this, see Table 2 in the review of [@B11].

###### 

IC~50~ values of selective late sodium current inhibitors for the late and the early sodium current component.

  Compound     IC~50~ for                 Reference                 
  ------------ -------------------------- ------------------------- ---------
  Lidocaine    29 µM                      367 µM                    [@B11]
  Ranolazine   17 µM                      1329 µM                   [@B19]
  6 µM         294 µM                     [@B186]                   
  GS-458967    333 nM                     \<15 % block at 333 nM    [@B95]
  130 nM       7.5 % reduction at 10 µM   [@B19]                    
  GS-462808    1.9 µM                     10 % reduction at 10 µM   [@B96]
  GS-6615      0.62 µM                    51 µM                     [@B211]
  F15845       3.25 µM                    23 % reduction at 10 µM   [@B187]

Where the IC~50~ value is missing, inhibition percentage at a given concentration was used instead.

For lidocaine, IC~50~ values of around 25 and 300 µM were determined for I~Na,late~ and I~Na,early~, respectively ([@B11]).

In case of ranolazine, the IC~50~ values are 17 µM for I~Na,late~ and 1,329 µM for I~Na,early~ in rabbit ([@B19]), whereas 6 µM for I~Na,late~ ([@B10]; [@B186]) and 294 µM for I~Na,early~ ([@B186]) in canine ventricular myocytes.

GS-458967 was found to have an IC~50~ of 333 nM for I~Na,late~ inhibition while exhibiting smaller than 15% block of I~Na,early~ at the same concentration at 1 and 3 Hz pacing frequencies ([@B95]) measured on Na~v~1.5 channels expressed in HEK-293 cells with automated patch-clamp. In rabbit ventricular cardiomyocytes, the IC~50~ was 130 nM for I~Na,late~, and at 10 µM, GS-458967 caused an approximately 7.5 % reduction in I~Na,early~. ([@B19]). Unfortunately for the developer, GS-458967 had a high brain penetration and a profound use dependent block on all the various sodium channel isoforms, making the compound prone for possible central nervous system side effects ([@B95]).

GS-462808 has an IC~50~ of 1.9 µM for I~Na,late~ inhibition while blocking 10 % of I~Na,early~ at 10 µM and it is also more cardiac isoform selective than GS-458967 blocking only 8 % of the Na~v~1.1 peak current. The problem with GS-462808 is that it caused liver lesions during the acute animal toxicity tests ([@B96]).

For GS-6615 the IC~50~ values of 0.62 and 51 µM were reported for I~Na,late~ and I~Na,early~ blockade, respectively, in manual patch-clamp experiments, with practically no effect on Na~v~1.1 channels ([@B211]).

F15845 has an IC~50~ of 3.25 µM for the inhibition of veratridine-induced I~Na,late~ while blocking 23 % of I~Na,early~ at 10 µM ([@B187]). Last experimental data about F15845 were published in 2010, where it prevented ischemia-induced arrhythmias in rats ([@B145]). Since then no new results came out regarding this agent.

Selectivity of these specific I~Na,late~ inhibitors is usually voltage-dependent, these blockers have very little effect on I~Na,early~ at more negative (quite unphysiological, for example −120 mV) holding potentials. As the holding potential gets closer to physiological resting membrane potentials, the selectivity of these compounds decrease, they start to inhibit I~Na,early~ more. Also, most inhibitors block the sodium channels in a rate-dependent ("use-dependent") fashion; the blockers are more effective at rapid than at slow heart rates. This is because most inhibitors preferentially bind to the open and/or inactivated channels rather than the closed channel. This effect is especially strong in sodium channel blockers having fast association and dissociation kinetics ([@B146]) (Vaughan-Williams class Ib agents).

In case of 1 µM GS-458967 for example, I~Na,early~ did not change in rabbit ventricular myocytes held at −120 mV at pacing rates of 0.1, 1, or 3 Hz. When the holding potential was −80 mV, however, 1 µM GS-458967 reduced I~Na,early~ by 48 ± 7%, 50 ± 7%, and 56 ± 8% at rates of 0.1, 1, and 3 Hz, respectively ([@B19]).

Ranolazine also inhibits sodium channels in a voltage-, and use-dependent fashion, moreover this blockade is also significantly larger in atria compared to ventricles ([@B217]). With 50 ms long depolarizing pulses and 250 ms diastolic intervals (at 3.33 Hz), the use-dependent block by ranolazine at −120 mV was 21 % in ventricular, versus 32 % in atrial cells, whereas at −100 mV the block was 47 % versus 56 %, respectively. This data suggest that the rate dependency (use-dependency) is very pronounced in case of I~Na,early~ inhibition, but much smaller with I~Na,late~. Therefore, based on the rate-dependent physiological (see *Heart Rate and AP Duration Influences I~Na,late~*) and pharmacological characteristics of I~Na,~ ~early~ and I~Na,late~, a quite selective inhibition of I~Na,late~ might be achieved at slow heart rates and with long APs, but at fast rates, with short AP duration, sodium channel blockers similarly inhibit both I~Na,~ ~early~ and I~Na,late~.

At therapeutical plasma concentrations, ranolazine inhibits other ionic currents besides I~Na,late~. This includes I~Kr~ (approximately 40 % inhibition at 6 µM), and I~Ca,L~ (around 25 % inhibition at 6 µM) ([@B10]). Consequently, inhibiting I~Na,late~ and applying ranolazine are very far from being identical concepts. When ranolazine is used to inhibit I~Na,late~, effects on other channels must not be forgotten. Besides the previous features, ranolazine is also a weak β-adrenergic antagonist ([@B100]) and an inhibitor of fatty acid oxidation ([@B46]), even though this latter effect only becomes prominent at supratherapeutical plasma concentrations.

Non-Cardiac Sodium Channel Inhibitors as Potential Antiarrhythmic Agents {#s5_3}
------------------------------------------------------------------------

Riluzole blocks TTX-sensitive sodium channels preferentially, which are associated with damaged neurons ([@B168]). Riluzole also directly inhibits the kainate and NMDA receptors ([@B58]) as well as potentiates GABA~A~ receptors ([@B76]). In anaesthetized pigs, myocardial damage and arrhythmias induced by coronary occlusion has been reduced by riluzole ([@B200]). Riluzole has also been found to be anti-ischemic and antiarrhythmic in a pig model of acute myocardial infarction. ([@B199]).

Targeting Na~v~1.8 with specific inhibitors might provide a potential novel approach in the future in antiarrhythmic drug therapy, because recent studies have found that Na~v~1.8 expression is significantly up-regulated in human left ventricular hypertrophy ([@B4]) and HF ([@B61]). By using Na~v~1.8-specific blockers \[either A-803467 (30 nM) or PF-01247324 (1 μM)\] the authors managed to reduce I~Na,late~ and APD in these experiments. Other Na~v~1.8 specific inhibitors include funapide and VX-150, however these compounds have not been tested in relation to cardiac pathophysiology so far.

Experimental Pathophysiology Studies {#s5_4}
------------------------------------

Because of the pronounced use-dependent effect of specific I~Na,late~ inhibitors, interpretation of experimental studies conducted on rats and mice (having resting heart rates around 400 bpm) are very difficult. Therefore this review will focus on experimental data originating from larger mammalian species.

### Late Sodium Current Inhibition and Ventricular Arrhythmias {#s5_4_1}

As it was demonstrated in the previous sections, I~Na,late~ has quite different characteristics under different heart rates. Therefore it is worthwhile to split the ventricular arrhythmia topic into two subtopics accordingly.

#### Bradycardia and Long APs {#s5_4_1_1}

Many *in vitro* experimental studies have shown that at low pacing rates with prolonged APs and increased repolarization heterogeneity (LQT3 syndrome, heart failure, hypertrophic cardiomyopathy), inhibition of I~Na,late~ effectively reduces the burden of arrhythmic episodes \[EADs, DADs, triggered APs, Torsade de Pointes (TdP) ([@B161]; [@B169]; [@B53]; [@B19]; [@B149])\].

Ranolazine and GS-458967 has been shown to suppress dofetilide-induced TdP in a canine in vivo model ([@B9]; [@B30]).

There was one experimental study about the potential antiarrhythmic role of F15845, where it prevented ischemia-induced arrhythmias in rats ([@B145]). However the use of a rat model makes it hard to extrapolate this study to humans.

Under the pathological conditions listed above, the fine balance between the inward and outward currents during the AP plateau is shifted toward the depolarizing inward currents, resulting in a longer AP. Therefore, theoretically, any intervention that reduces the depolarizing currents (e.g.: L-type calcium current, NCX current, I~Na,late~) could be effective in bringing the repolarization closer to normal. In this setting, therefore, inhibiting I~Na,late~ will reduce the depolarization drive resulting in a significantly shorter APD and the suppression of arrhythmogenic events such as EADs, even if the magnitude of I~Na,late~ is not increased. Under similar conditions, other interventions such as L-type calcium channel blockade ([@B1]) or potassium channel activation ([@B38]) can also shorten APD, reduce repolarization heterogeneity, and suppress the occurrence of arrhythmogenic events even if I~Na,late~ is upregulated. In LQT syndromes I~Na,late~-mediated increase in Ca^2+^~i~ is just a fraction of the total Ca^2+^~i~, and even total Ca^2+^~i~ just contributes to rather than determines the arrhythmogenic events ([@B39]).

#### Tachycardia-Induced Tachyarrhythmias (VT, VF) {#s5_4_1_2}

I~Na,late~ blockers seem to effectively prevent or terminate tachycardia-induced ventricular tachycardia, and ventricular fibrillation in healthy animal models in the presence of a β-adrenergic agonist ([@B7]; [@B42]; [@B13]).

However, inhibition of I~Na,late~ does not likely play a crucial role here, based on the following theoretical considerations. To start with, in healthy ventricular tissue at high heart rates I~Na,late~ is quite small, as it was discussed in *Heart Rate and AP Duration Influences I~Na,late~*. Furthermore, at rapid heart rates with β-adrenergic stimulation the major arrhythmogenic mechanism is likely to be the increased L-type calcium current, the increased SR Ca^2+^ content, and the leaky RyR together ([@B129]). The third but similarly important factor is that these VT/VF episodes are likely underlain by a reentry mechanism, therefore heavily depending on the fast conduction provided by I~Na,early~. At high pacing rates the "specific" I~Na,late~ inhibitors will also block a considerable amount of I~Na,early~ as well (see *Selective I~Na,late~ Inhibitors* for details), and this might just be enough to break the reentry circuit ([@B33]).

Based on the experimental data, I~Na,late~ inhibition seems to be a valid therapeutic approach to tackle ventricular arrhythmias especially at low heart rates. These experimental studies also suggest that I~Na,late~ inhibition mainly affects the arrhythmogenic substrate by making the repolarization less heterogenous ([@B42]), with only low impact on suppressing the triggers ([@B30]).

### Late Sodium Current Inhibition in AF {#s5_4_2}

GS-458967 was shown to suppress isoproterenol-, and high Ca^2+^-induced DADs in healthy canine pulmonary-, and superior vena cava preparations ([@B166]). GS-458967 also suppressed autonomically triggered AF in an intact porcine model ([@B42]). In other experimental studies, "classic" sodium channel inhibitors (eg, lidocaine, flecainide) also prevented and terminated AF ([@B193]; [@B52]). However, these agents were used at concentrations causing a suppression of I~Na,early~. Experimental data about ranolazine shows an effective reduction of AF burden (AFB) only at concentrations that potently inhibit both I~Na,early~ ([@B34]; [@B98]; [@B35]) and I~Kr~ ([@B34]) Suppressing I~Kr~ reduces the diastolic interval between APs therefore promoting rate-dependent I~Na,early~ inhibition.

Based on these data, *specific* I~Na,late~ blockade alone is not a clear and straightforward approach in AF, except for cases when a longer atrial AP is the pathogenetic factor in the initiation of AF.

Clinical Studies {#s5_5}
----------------

### Ranolazine {#s5_5_1}

So far, ranolazine has been used in the vast majority of clinical studies involving I~Na,late~ blockers. When interpreting these trials, it has to be considered that ranolazine has other effects besides inhibiting I~Na,late~. With the use of ranolazine, the first favorable results from phase 2 clinical trials were published in the 1990s ([@B50]; [@B181]). In 2006, following the outcome of the MARISA ([@B44]), CARISA ([@B45]), and ERICA ([@B175]) trials, the Food and Drug Administration approved ranolazine as an anti-anginal agent.

The effect of clinical outcome and safety of ranolazine therapy was investigated in more than 6,500 patients with non-ST-elevation acute coronary syndrome in the MERLIN TIMI-36 trial ([@B135]). Although cardiovascular death or myocardial infarction has not been significantly reduced by ranolazine when compared to standard therapy; but recurrent ischemia ([@B135]) and the incidence of arrhythmias ([@B160]) were significantly lower with ranolazine. Treatment with ranolazine, compared to placebo, resulted in significantly lower incidences of arrhythmias. Fewer patients had episodes of ventricular tachycardia lasting more than eight beats \[166 (5.3%) versus 265 (8.3%); p\<0.001\], supraventricular tachycardia \[1413 (44.7%) versus 1752 (55.0%); p\<0.001\], or new-onset AF \[55 (1.7%) versus 75 (2.4%); p=0.08\]. Moreover, longer than 3 s pauses were less frequent with ranolazine \[97 (3.1%) versus 136 (4.3%); p=0.01\].

In the double-blind HARMONY (ClinicalTrials.gov ID: NCT01522651) phase 2 trial ([@B151]), patients with paroxysmal AF and implanted pacemakers were enrolled, so that AFB could continuously be monitored over the 12 weeks of treatment period. Patients were randomized to placebo, ranolazine alone (750 mg twice a day---BID), dronedarone alone (225 mg BID), or ranolazine (750 mg BID) combined with dronedarone (either 150 mg BID or 225 mg BID). The idea behind the combination was to reduce the dose of dronedarone, and therefore the negative inotropic effect associated with dronedarone. Placebo or the drugs alone did not significantly reduce AFB. In the combination therapies, however, ranolazine with dronedarone 225 mg BID reduced AFB by 59% vs placebo (p=0.008), and ranolazine with dronedarone 150 mg BID reduced AFB by 43% (p=0.072). Also, patients tolerated both combinations well.

Into the RAFFAELLO phase 2 trial ([@B56]) patients with persistent AF (7 days to 6 months) were enrolled. Two hours after successful electrical cardioversion participants were randomized to either placebo, or ranolazine 375 mg, 500 mg, or 750 mg BID. Patients were monitored daily by transtelephonic ECG. The primary end-point was the time to first AF recurrence. No dose of the ranolazine prolonged time to AF recurrence significantly compared to placebo. Of the 238 patients who took at least one dose of the study drug, AF recurred in 56.4%, 56.9%, 41.7%, and 39.7% of patients in the placebo and ranolazine 375 mg/500 mg/750 mg groups, respectively. The reduction in overall AF recurrence in the combined 500-mg and 750-mg groups was of borderline significance compared to the placebo group (p=0.053) and significant compared to 375-mg group (p=0.035).

The RAID clinical trial (NCT01534962) ([@B212]) investigated high-risk cardiomyopathy patients who received an implantable cardioverter-defibrillator (ICD). The subjects received either ranolazine (1,000 mg BID) or placebo. The primary endpoints were VT or VF requiring ICD shock or death. Among 1,012 ICD patients the ranolazine versus placebo hazard ratio was 0.84 (95% confidence interval: 0.67 to 1.05; p=0.117) for the primary endpoint. In the ranolazine group the risk of ICD therapies for recurrent VT or VF were significantly lower (hazard ratio: 0.70; 95% confidence interval: 0.51 to 0.96; p=0.028). Other effects of ranolazine treatment however has not been significant. These included individual components of the primary endpoint, quality of life, cardiac hospitalizations, and inappropriate ICD shocks as well.

In a smaller group of participants of the RAND-CFR trial (NCT01754259) ([@B64]) where symptomatic diabetic patients participated with non-flow-limiting coronary artery stenosis with diffuse atherosclerosis and/or microvascular dysfunction, effect of ranolazine on T-wave heterogeneity was evaluated. At physical rest, in the ranolazine group T-wave heterogeneity was 28 % smaller (placebo: 47±6 μV, ranolazine: 39±5 μV, p=0.002), however ranolazine did not differ from the placebo group during exercise. The trial also suggested that reduction in repolarization abnormalities seemed to be independent of alterations in myocardial blood flow.

In a meta-analysis of eight randomized clinical trials ([@B69]) *Gong et al*. found that ranolazine significantly reduced AF incidence in different clinical settings, such as in acute coronary syndromes, after cardiac surgery and after electrical cardioversion of AF (relative risk=0.67, 95% confidence interval: 0.52--0.87, p=0.002). Moreover, the combined use of ranolazine and amiodarone compared to amiodarone alone showed a 1.23-times higher conversion rate of AF (95% confidence interval: 1.08--1.40), together with a significantly, about 10 h shorter conversion time.

Based on the evidence above, ranolazine may have therapeutic role in the treatment of cardiac rhythm disorders, of both atrial and ventricular origin. For stronger evidence, more phase 3 clinical investigations are necessary.

### Eleclazine (GS-6615) {#s5_5_2}

Besides ranolazine, until now eleclazine was the only other selective I~Na,late~ inhibitor drug candidate that made it to phase 3 clinical trials. In the first trial (NCT02300558) eleclazine was tested for safety, tolerability, and its effect on shortening of the QT interval in LQT3 patients. The primary outcome of the study showed that after 24 weeks the mean daytime corrected QT interval was significantly, 8.5 ms shorter than at baseline, and there was only one patient with a serious adverse event (nephrolithiasis). The other trial (LIBERTY-HCM; NCT02291237) targeted HCM patients for the effect of eleclazine on exercise capacity. In this trial, eleclazine has not been proven to be superior to placebo.

The last moment in the development of eleclazine came after results of the phase 2 TEMPO study (NCT02104583) were analyzed. In the trial, subjects with ventricular tachycardia/ventricular fibrillation and ICD participated. Results of the study have shown that the rate of ICD shocks was higher in subjects who received eleclazine compared to the placebo arm. Therefore in late 2016, the further development of eleclazine was terminated for all indications.

Conclusions {#s6}
===========

An increased I~Na,late~ is present in many heart diseases. The upregulated I~Na,late~ lengthens the cardiac AP, increases \[Na^+^\]~i~, and causes Ca^2+^ overload of cardiomyocytes by offsetting the forward mode NCX. The elevated Ca^2+^, in turn, mainly through CaMKII, can further increase I~Na,late~ in a vicious circle. These pathophysiological mechanisms together may result in impaired cardiac energetics and contractile dysfunction of the heart as well as cardiac arrhythmias. The prolonged AP can serve as a substrate that is prone to rhythm disorders, whereas Ca^2+^ overload can be the trigger. I~Na,late~ seems to possess a pathogenetic role especially in AF and in ventricular arrhythmias occurring under bradycardic conditions.

Multitude of pathophysiology studies have drawn the consequence that selective I~Na,late~ inhibition is a favorable antiarrhythmic tool in many experimental settings. Despite all these studies, the one and only drug on the market that selectively inhibits I~Na,late~ is ranolazine, although it significantly affects other ionic currents as well. Ranolazine has been a safe and effective antianginal medication since 2006 based on large randomized studies. Some recent clinical evidence also proves that ranolazine shows favorable effects in AF and in ventricular arrhythmias. For stronger evidence, more phase 3 clinical investigations are necessary. Targeting Na~v~1.8 with specific inhibitors is also an interesting novel approach in the future of antiarrhythmic drug therapy.
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